# QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

> **NCT06404463** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 76 (estimated)

## Conditions studied

- Early Breast Cancer
- Neoadjuvant Therapy
- HR+HER2- Breast Cancer

## Interventions

- **DRUG:** QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- **DRUG:** Albumin-bound paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT06404463
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2025-11-06
- **Final completion:** 2030-11-06
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06404463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06404463, "QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06404463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*